Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double Blind Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

NCT04665843 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04665843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04665843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double Blind Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
March 2, 2021
Completion date
August 27, 2025
Enrollment
123 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of head and neck